Kōichi Goto

24.2k total citations · 5 hit papers
497 papers, 10.8k citations indexed

About

Kōichi Goto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kōichi Goto has authored 497 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 323 papers in Pulmonary and Respiratory Medicine, 294 papers in Oncology and 124 papers in Molecular Biology. Recurrent topics in Kōichi Goto's work include Lung Cancer Treatments and Mutations (289 papers), Lung Cancer Research Studies (136 papers) and Lung Cancer Diagnosis and Treatment (100 papers). Kōichi Goto is often cited by papers focused on Lung Cancer Treatments and Mutations (289 papers), Lung Cancer Research Studies (136 papers) and Lung Cancer Diagnosis and Treatment (100 papers). Kōichi Goto collaborates with scholars based in Japan, United States and South Korea. Kōichi Goto's co-authors include Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Shingo Matsumoto, Yutaka Nishiwaki, Hironobu Ohmatsu, Yuichiro Ohe, Takashi Seto, Nobuyuki Yamamoto and Makoto Nishio and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Nature Genetics.

In The Last Decade

Kōichi Goto

475 papers receiving 10.6k citations

Hit Papers

Erlotinib alone or with bevacizumab as first-line therapy... 2014 2026 2018 2022 2014 2017 2020 2018 2022 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
    2014 561 citations Takashi Seto, Terufumi Kato et al. profile →
  2. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
    2017 308 citations Takashi Seto, Makoto Nishio et al. profile →
  3. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 303 citations Kōichi Goto, Yuichiro Ohe et al. Annals of Oncology profile →
  4. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
    2018 225 citations James Chih‐Hsin Yang, Takashi Seto et al. Journal of Clinical Oncology profile →
  5. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kōichi Goto Japan 50 6.6k 6.4k 3.4k 1.9k 1.2k 497 10.8k
Katsuyuki Kiura Japan 54 7.6k 1.2× 8.2k 1.3× 3.9k 1.1× 1.9k 1.0× 1.0k 0.9× 578 12.5k
Noboru Yamamoto Japan 54 7.3k 1.1× 5.3k 0.8× 3.3k 1.0× 1.6k 0.8× 855 0.7× 513 11.8k
Marina Chiara Garassino Italy 46 7.5k 1.1× 6.4k 1.0× 2.4k 0.7× 1.5k 0.8× 1.1k 0.9× 309 10.6k
Daniel Morgensztern United States 36 5.4k 0.8× 4.5k 0.7× 3.9k 1.2× 2.2k 1.1× 1.9k 1.6× 228 10.4k
Nick Pavlakis Australia 45 4.9k 0.7× 3.5k 0.5× 1.9k 0.6× 1.6k 0.8× 951 0.8× 307 8.6k
Jin Seok Ahn South Korea 55 8.6k 1.3× 7.8k 1.2× 3.2k 1.0× 3.0k 1.6× 926 0.8× 452 13.5k
Balázs Halmos United States 48 8.0k 1.2× 7.6k 1.2× 4.9k 1.5× 2.2k 1.1× 521 0.4× 280 12.7k
Nobuyuki Yamamoto Japan 58 11.6k 1.8× 12.5k 2.0× 4.0k 1.2× 2.5k 1.3× 1.2k 1.0× 574 17.3k
Tarek Mekhail United States 41 5.8k 0.9× 6.9k 1.1× 3.0k 0.9× 1.8k 1.0× 462 0.4× 170 10.6k
Yasuhide Yamada Japan 55 5.3k 0.8× 3.8k 0.6× 4.3k 1.3× 1.9k 1.0× 749 0.6× 308 10.9k

Countries citing papers authored by Kōichi Goto

Since Specialization
Citations

This map shows the geographic impact of Kōichi Goto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kōichi Goto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kōichi Goto more than expected).

Fields of papers citing papers by Kōichi Goto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kōichi Goto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kōichi Goto. The network helps show where Kōichi Goto may publish in the future.

Co-authorship network of co-authors of Kōichi Goto

This figure shows the co-authorship network connecting the top 25 collaborators of Kōichi Goto. A scholar is included among the top collaborators of Kōichi Goto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kōichi Goto. Kōichi Goto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spira, Alexander I., Byoung Chul Cho, Enriqueta Felip, et al.. (2024). PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004). Journal of Thoracic Oncology. 19(7). e17–e18.
2.
3.
Matsumoto, Yoshihisa, Shigeki Umemura, Daisuke Fujisawa, et al.. (2024). Nurse‐Led Screening‐Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial. Cancer Medicine. 13(22). e70325–e70325. 1 indexed citations
4.
5.
Shimokawa, Tsuneo, Hiroaki Okamoto, Ryunosuke Machida, et al.. (2023). Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer. 181. 107195–107195. 4 indexed citations
6.
7.
Jänne, Pasi A., Yasushi Goto, Toshio Kubo, et al.. (2023). MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02. Journal of Thoracic Oncology. 18(11). S148–S148. 2 indexed citations
8.
Loong, Herbert H., Gennaro Daniele, Ticiana Leal, et al.. (2023). 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Annals of Oncology. 34. S761–S762. 4 indexed citations
9.
Schram, Alison M., Kōichi Goto, Dongwook Kim, et al.. (2023). 1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S756–S757. 10 indexed citations
10.
Yoshida, Tatsuya, Toru Kumagai, Ryo Toyozawa, et al.. (2023). Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial. Cancer Science. 114(9). 3698–3707. 7 indexed citations
11.
Ohtsu, Atsushi, Kōichi Goto, & Takayuki Yoshino. (2023). Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. Proceedings of the Japan Academy Series B. 99(8). 241–253. 3 indexed citations
12.
Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →
13.
Naito, Tomoyuki, Hibiki Udagawa, Kōichi Goto, et al.. (2022). Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy. Cancer Science. 114(2). 630–639. 6 indexed citations
14.
Kashima, Yukie, Ayako Suzuki, Ikei S. Kobayashi, et al.. (2021). Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Research. 81(18). 4835–4848. 49 indexed citations
15.
Tanimoto, Azusa, Shingo Matsumoto, Shinji Takeuchi, et al.. (2020). Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression. Clinical Cancer Research. 27(5). 1410–1420. 38 indexed citations
16.
Udagawa, Hibiki, Akihiro Ohashi, Naomi Abe, et al.. (2019). TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Molecular Cancer Research. 17(11). 2233–2243. 55 indexed citations
17.
Makinoshima, Hideki, Shigeki Umemura, Ayako Suzuki, et al.. (2018). Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer Research. 78(9). 2179–2190. 33 indexed citations
18.
Nukaga, Shigenari, Hiroyuki Yasuda, Katsuya Tsuchihara, et al.. (2017). Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research. 77(8). 2078–2089. 131 indexed citations
19.
Miyoshi, Tomohiro, Shigeki Umemura, Yuki Matsumura, et al.. (2016). Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research. 23(3). 757–765. 139 indexed citations
20.
Yoshida, Tatsuya, Genichiro Ishii, Kōichi Goto, et al.. (2014). Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research. 21(3). 642–651. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsuyuki Kiura Breakdown of academic impact, for papers by Noboru Yamamoto Breakdown of academic impact, for papers by Marina Chiara Garassino Breakdown of academic impact, for papers by Daniel Morgensztern Breakdown of academic impact, for papers by Nick Pavlakis Breakdown of academic impact, for papers by Jin Seok Ahn Breakdown of academic impact, for papers by Balázs Halmos Breakdown of academic impact, for papers by Nobuyuki Yamamoto Breakdown of academic impact, for papers by Tarek Mekhail Breakdown of academic impact, for papers by Yasuhide Yamada
Rankless by CCL
2026